Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders
Ontology highlight
ABSTRACT: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, the responses to ICI treatment are highly variable in different individuals and the underlying mechanisms remain poorly understood.
ORGANISM(S): Mus musculus
PROVIDER: GSE227404 | GEO | 2023/03/17
REPOSITORIES: GEO
ACCESS DATA